DE3855135T2 - 2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen - Google Patents

2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen

Info

Publication number: DE3855135T2
Authority: DE; Germany
Prior art keywords: compound; phosphorothioat; oligoadenylates; thioadenylyl; water
Prior art date: 1987-10-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE3855135T

Other languages

English (en)

Other versions

DE3855135D1 (de

Inventor

Robert Suhadolnik

Wolfgang Pfleiderer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Temple University of Commonwealth System of Higher Education

Original Assignee

Temple University of Commonwealth System of Higher Education

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-10-22

Filing date

1988-10-18

Publication date

1996-09-05

1988-10-18 Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education

1996-04-25 Application granted granted Critical

1996-04-25 Publication of DE3855135D1 publication Critical patent/DE3855135D1/de

1996-09-05 Publication of DE3855135T2 publication Critical patent/DE3855135T2/de

2008-10-19 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

DE3855135T 1987-10-22 1988-10-18 2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen Expired - Fee Related DE3855135T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/112,591 US4924624A (en)	1987-10-22	1987-10-22	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
PCT/US1988/003634 WO1989003683A1 (en)	1987-10-22	1988-10-18	2',5'-phosphorothioate oligoadenylates and antiviral uses thereof

Publications (2)

Publication Number	Publication Date
DE3855135D1 DE3855135D1 (de)	1996-04-25
DE3855135T2 true DE3855135T2 (de)	1996-09-05

Family

ID=22344763

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE3856326T Expired - Fee Related DE3856326T2 (de)	1987-10-22	1988-10-18	2'-5'-Phosphorothioat-Oligoadenylate und deren antivirale Verwendungen
DE3855135T Expired - Fee Related DE3855135T2 (de)	1987-10-22	1988-10-18	2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE3856326T Expired - Fee Related DE3856326T2 (de)	1987-10-22	1988-10-18	2'-5'-Phosphorothioat-Oligoadenylate und deren antivirale Verwendungen

Country Status (8)

Country	Link
US (3)	US4924624A (de)
EP (2)	EP0694559B1 (de)
JP (1)	JP2733777B2 (de)
AT (2)	ATE135579T1 (de)
AU (1)	AU2628088A (de)
CA (1)	CA1339953C (de)
DE (2)	DE3856326T2 (de)
WO (1)	WO1989003683A1 (de)

Families Citing this family (838)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5550111A (en) *	1984-07-11	1996-08-27	Temple University-Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5643889A (en) *	1984-07-11	1997-07-01	Temple University-Of The Commonwealth System Of Pennsylvania	Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
US4924624A (en) *	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
JP2976436B2 (ja) *	1988-04-27	1999-11-10	味の素株式会社	新規オリゴリボヌクレオチド誘導体及び抗ウイルス剤への使用
ATE269870T1 (de) *	1989-10-24	2004-07-15	Isis Pharmaceuticals Inc	2'-modifizierte oligonukleotide
US5635488A (en) *	1991-10-15	1997-06-03	Isis Pharmaceuticals, Inc.	Compounds having phosphorodithioate linkages of high chiral purity
US6339066B1 (en)	1990-01-11	2002-01-15	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5620963A (en) *	1991-10-15	1997-04-15	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5587361A (en) *	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5470967A (en) *	1990-04-10	1995-11-28	The Dupont Merck Pharmaceutical Company	Oligonucleotide analogs with sulfamate linkages
US6446032B1 (en) *	1990-09-21	2002-09-03	Massachusetts Institute Of Technology	Designing compounds specifically inhibiting ribonucleic acid by binding to the minor groove
US6041910A (en) *	1997-09-22	2000-03-28	Jervis B. Webb Company	Baggage pusher device and system
GB9111967D0 (en) *	1991-06-04	1991-07-24	Erba Carlo Spa	2,5'-nucleotide analogs as antiviral agents
US5571799A (en) *	1991-08-12	1996-11-05	Basco, Ltd.	(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
WO1993003733A1 (en) *	1991-08-12	1993-03-04	Basco, Ltd.	Syntheses, pharmaceutical composition and method of application of (2'-5') oligoadenylate analogues
US5607923A (en) *	1991-10-15	1997-03-04	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5654284A (en) *	1991-10-15	1997-08-05	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5661134A (en) *	1991-10-15	1997-08-26	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5576302A (en) *	1991-10-15	1996-11-19	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5599797A (en) *	1991-10-15	1997-02-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
AU664883B2 (en) *	1992-03-12	1995-12-07	Temple University - Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US6537973B1 (en)	1992-03-16	2003-03-25	Isis Pharmaceuticals, Inc.	Oligonucleotide inhibition of protein kinase C
US20040127446A1 (en) *	1992-05-14	2004-07-01	Lawrence Blatt	Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5532130A (en) *	1993-07-20	1996-07-02	Dyad Pharmaceutical Corporation	Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
US6653458B1 (en)	1993-09-03	2003-11-25	Isis Pharmaceuticals, Inc.	Modified oligonucleotides
CA2170869C (en)	1993-09-03	1999-09-14	Phillip Dan Cook	Amine-derivatized nucleosides and oligonucleosides
US7276335B1 (en) *	1993-09-29	2007-10-02	Massachusetts Institute Of Technology	Designing compounds specifically inhibiting ribonucleic acid function
NZ291713A (en) *	1994-09-14	1998-01-26	Univ Temple	2',5'-phosphorothioate/phosphodiester oligoadenylates
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
US5855911A (en) *	1995-08-29	1999-01-05	Board Of Regents, The University Of Texas System	Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US20040171028A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US20050119470A1 (en) *	1996-06-06	2005-06-02	Muthiah Manoharan	Conjugated oligomeric compounds and their use in gene modulation
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US20040171031A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20050042647A1 (en) *	1996-06-06	2005-02-24	Baker Brenda F.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US6111085A (en)	1996-09-13	2000-08-29	Isis Pharmaceuticals, Inc.	Carbamate-derivatized nucleosides and oligonucleosides
US6977244B2 (en)	1996-10-04	2005-12-20	Board Of Regents, The University Of Texas Systems	Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6468991B1 (en)	1997-01-16	2002-10-22	Cyclis Pharmaceuticals, Inc.	Method of treating rhinoviral infections
US5955446A (en) *	1997-01-16	1999-09-21	Pentose Pharmaceuticals, Inc.	Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds
WO1998056384A1 (en)	1997-06-12	1998-12-17	Temple University - Of The Commonwealth System Of Higher Education	Aminoaklanoyl-linked conjugates of 2',5'-oligoadenylate and antiviral uses thereof
US6281201B1 (en)	1997-06-12	2001-08-28	Temple University- Of The Commonwealth System Of Higher Education	Base-modified derivatives of 2′,5′-oligoadenylate and antiviral uses thereof
DE69834038D1 (de)	1997-07-01	2006-05-18	Isis Pharmaceutical Inc	Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
AU8512598A (en) *	1997-07-25	1999-02-16	Hybridon, Inc.	Oligonuclotides having 3' terminal stereospecific phosphorothioates
US7285288B1 (en)	1997-10-03	2007-10-23	Board Of Regents, The University Of Texas System	Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en)	1997-10-03	2010-04-27	Board Of Regents, The University Of Texas System	Small oligonucleotides with anti-tumor activity
US6958148B1 (en)	1998-01-20	2005-10-25	Pericor Science, Inc.	Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en)	1998-01-20	2005-07-19	Pericor Science, Inc.	Conjugates of agents and transglutaminase substrate linking molecules
AU770896C (en) *	1998-09-29	2006-09-07	Gamida Cell Ltd.	Methods of controlling proliferation and differentiation of stem and progenitor cells
US7321828B2 (en)	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
US20040186071A1 (en) *	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
CA2329130A1 (en) *	1998-05-21	1999-11-25	Isis Pharmaceuticals Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
EP1080226A4 (de) *	1998-05-21	2004-04-21	Isis Pharmaceuticals Inc	Zusammensetzungen und methoden zur topischen verabreichung von oligonukleotiden
US6461815B1 (en) *	1998-05-22	2002-10-08	North Carolina State University	Antibacterial agents and methods of screening for the same
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) *	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US7534605B2 (en)	1999-06-08	2009-05-19	Yissum Research Development Company Of The Hebrew University Of Jerusalem	CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6593466B1 (en)	1999-07-07	2003-07-15	Isis Pharmaceuticals, Inc.	Guanidinium functionalized nucleotides and precursors thereof
DE19940748A1 (de) *	1999-08-27	2001-03-01	Hugo Seinfeld	Arzneimittel enthaltend xenogene Oligo- oder/und Polyribonukleotide
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
EP2202241A3 (de) *	2000-04-13	2010-07-28	Thomas N. Wight	Therapeutische Verbindungen und Verfahren zur V3-Modulation, einer Versican-Isoform
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US6656700B2 (en) *	2000-05-26	2003-12-02	Amersham Plc	Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) *	2000-05-26	2004-02-03	Amersham Plc	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US20060166227A1 (en) *	2000-06-20	2006-07-27	Stephen Kingsmore	Protein expression profiling
US6323009B1 (en) *	2000-06-28	2001-11-27	Molecular Staging, Inc.	Multiply-primed amplification of nucleic acid sequences
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
US20020123474A1 (en) *	2000-10-04	2002-09-05	Shannon Mark E.	Human GTP-Rho binding protein2
WO2002030465A2 (en)	2000-10-12	2002-04-18	University Of Rochester	Compositions that inhibit proliferation of cancer cells
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
KR20020069627A (ko) *	2001-02-27	2002-09-05	동부한농화학 주식회사	육환의 아자슈거를 가진 뉴클레오타이드 유도체를 포함한포스포로티오에이트 올리고뉴클레오타이드 및 이들의에이즈 치료제로서의 새로운 용도
ES2328796T3 (es)	2001-03-14	2009-11-18	Myriad Genetics, Inc.	Interaccion tsg101-gag y uso de la misma.
KR100788092B1 (ko)	2001-06-20	2007-12-21	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
CA2790034A1 (en)	2001-06-21	2003-01-03	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
DE10133858A1 (de)	2001-07-12	2003-02-06	Aventis Pharma Gmbh	Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
US6822088B2 (en)	2001-07-17	2004-11-23	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides on solid support
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
CA2455424A1 (en) *	2001-08-07	2003-02-20	University Of Delaware	Compositions and methods for the prevention and treatment of huntington's disease
US20040096880A1 (en) *	2001-08-07	2004-05-20	Kmiec Eric B.	Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
DE60238143D1 (de)	2001-09-18	2010-12-09	Genentech Inc	Zusammensetzungen und verfahren für die diagnose von tumoren
NZ585001A (en)	2001-10-09	2011-08-26	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
MXPA04006554A (es)	2002-01-02	2005-03-31	Genentech Inc	Composiciones y metodos para diagnostico y tratamiento de tumor.
IL152904A0 (en)	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) *	2002-01-25	2003-07-31	Gamida-Cell Ltd.	Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US7553619B2 (en) *	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
EP2011886A3 (de)	2002-04-16	2009-02-11	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US20030199464A1 (en)	2002-04-23	2003-10-23	Silviu Itescu	Regeneration of endogenous myocardial tissue by induction of neovascularization
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
AU2003231912A1 (en) *	2002-06-12	2003-12-31	Tel Aviv Medical Center Research Development Fund	Methods of detecting and treating prostate cancer
AU2003276131A1 (en) *	2002-06-18	2003-12-31	Epigenesis Pharmaceuticals, Inc.	A dry powder oligonucleotide formulation, preparation and its uses
US20050287648A1 (en)	2002-08-05	2005-12-29	University Of Rochester	Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
CA2498777C (en)	2002-09-13	2015-01-13	Replicor, Inc.	Non-sequence complementary antiviral oligonucleotides
EP2233494A3 (de) *	2002-09-20	2013-05-29	Yale University	Riboswitches, Verfahren für deren Anwendung, Zusammensetzungen damit
EP2272958A1 (de)	2002-09-26	2011-01-12	ISIS Pharmaceuticals, Inc.	Modulierung von der Forkheadbox O1A-Expression
EP1560597A4 (de) *	2002-10-29	2007-06-27	Pharmacia Corp	Differentiell ausgedrückte krebsgene, dabei kodierte polypeptide und verfahren zu ihrer verwendung
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US8604183B2 (en)	2002-11-05	2013-12-10	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9827263B2 (en)	2002-11-05	2017-11-28	Ionis Pharmaceuticals, Inc.	2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
SI1569695T1 (sl)	2002-11-13	2013-08-30	Genzyme Corporation	Protismiselna modulacija ekspresije apolipoproteina B
CA2505801A1 (en)	2002-11-13	2004-05-27	Rosanne Crooke	Antisense modulation of apolipoprotein b expression
US20060009378A1 (en) *	2002-11-14	2006-01-12	Itshak Golan	Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
WO2004046330A2 (en)	2002-11-15	2004-06-03	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
AU2003298650B2 (en)	2002-11-15	2010-03-11	Musc Foundation For Research Development	Complement receptor 2 targeted complement modulators
WO2004047749A2 (en)	2002-11-21	2004-06-10	University Of Utah Research Foundation	Purinergic modulation of smell
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
CA2510587A1 (en)	2002-12-20	2004-07-15	Qiagen Gmbh	Nucleic acid amplification
US6977153B2 (en) *	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
EP1597366B1 (de)	2003-02-11	2012-11-21	Antisense Therapeutics Ltd	Modulation der expression des insulinähnlichen wachstumsfaktor i-rezeptors
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US20040198640A1 (en) *	2003-04-02	2004-10-07	Dharmacon, Inc.	Stabilized polynucleotides for use in RNA interference
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
AU2004231740A1 (en) *	2003-04-17	2004-11-04	The Trustees Of Columbia University In The City Ofnew York	Desmoglein 4 is a novel gene involved in hair growth
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
EP2241572A3 (de)	2003-06-03	2011-04-06	Eli Lilly And Company	Modulation d'expression de survivine
ES2905724T3 (es)	2003-06-13	2022-04-11	Alnylam Europe Ag	Acido ribonucleico bicatenario con elevada eficacia en un organismo
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) *	2003-09-11	2007-05-31	Replicor Inc.	Oligonucleotides targeting prion diseases
CA2538252C (en) *	2003-09-18	2014-02-25	Isis Pharmaceuticals, Inc.	4'-thionucleosides and oligomeric compounds
EP2256201A3 (de)	2003-09-18	2012-07-04	Isis Pharmaceuticals, Inc.	Modulation der eIF4E expression
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
EP2412725A3 (de)	2003-11-17	2012-04-25	Genentech, Inc.	Antikörper gegen CD79b zur Behandlung von Tumoren hämatopoetischen Ursprungs
WO2005056571A1 (en) *	2003-12-05	2005-06-23	Biovitrum Ab	Improved synthesis of 2-substituted adenosines
JP2007520222A (ja)	2004-01-20	2007-07-26	アイシスファーマシューティカルズインコーポレイテッド	グルココルチコイドレセプター発現の調節
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US7842459B2 (en)	2004-01-27	2010-11-30	Compugen Ltd.	Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2005071058A2 (en) *	2004-01-27	2005-08-04	Compugen Ltd.	Methods and systems for annotating biomolecular sequences
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005089268A2 (en)	2004-03-15	2005-09-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of rna by rnase h
KR101147147B1 (ko)	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20050244869A1 (en) *	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
AU2005230684B2 (en)	2004-04-05	2011-10-06	Alnylam Pharmaceuticals, Inc.	Process and reagents for oligonucleotide synthesis and purification
US20050260755A1 (en) *	2004-04-06	2005-11-24	Isis Pharmaceuticals, Inc.	Sequential delivery of oligomeric compounds
JP4584987B2 (ja)	2004-04-30	2010-11-24	アルニラムファーマスーティカルズインコーポレイテッド	Ｃ５修飾ピリミジンを含むオリゴヌクレオチド
CA2564251C (en)	2004-05-21	2018-04-10	The Uab Research Foundation	Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
US20080261904A1 (en) *	2004-06-03	2008-10-23	Balkrishen Bhat	Chimeric Gapped Oligomeric Compounds
US20090048192A1 (en) *	2004-06-03	2009-02-19	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
EP1765416A4 (de) *	2004-06-03	2010-03-24	Isis Pharmaceuticals Inc	Doppelsträngige zusammensetzungen mit unterschiedlich modifizierten strängen zur verwendung bei der genmodulation
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
EP1799812A4 (de) *	2004-09-16	2009-09-09	Gamida Cell Ltd	Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
PL1809303T3 (pl) *	2004-09-23	2019-11-29	Arc Medical Devices Inc	Kompozycje farmaceutyczne i sposoby dotyczące hamowania zrostów włóknistych lub stanów zapalnych przy użyciu fukanów o niskiej zawartości siarczanów
WO2006050999A2 (en) *	2004-11-15	2006-05-18	Obe Therapy Biotechnology S.A.S	Methods of reducing body fat
US7935811B2 (en)	2004-11-22	2011-05-03	Dharmacon, Inc.	Apparatus and system having dry gene silencing compositions
US7923207B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Apparatus and system having dry gene silencing pools
US7923206B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Method of determining a cellular response to a biological agent
JP2008535796A (ja)	2005-03-10	2008-09-04	ジェネンテック・インコーポレーテッド	脈管の完全性を調節するための方法及び組成物
US7476733B2 (en) *	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8309303B2 (en) *	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
WO2007008300A2 (en)	2005-05-31	2007-01-18	ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE	Triblock copolymers for cytoplasmic delivery of gene-based drugs
WO2006133022A2 (en)	2005-06-03	2006-12-14	The Johns Hopkins University	Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
CN101273130B (zh) *	2005-07-07	2012-05-30	耶路撒冷希伯来大学伊森姆研究发展公司	用于下调h19的核酸物质及其使用方法
DK2239327T3 (en)	2005-08-11	2015-05-18	Synthetic Genomics Inc	A method for in vitro recombination
CA2617693A1 (en)	2005-08-17	2007-02-22	Medexis S.A.	Composition and method for determination of ck19 expression
WO2007027775A2 (en)	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
IL172297A (en)	2005-10-03	2016-03-31	Compugen Ltd	Soluble vegfr-1 variants for the diagnosis of preeclampsia
AU2006304321B2 (en)	2005-10-14	2012-10-04	Musc Foundation For Research Development	Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP1941059A4 (de)	2005-10-28	2010-11-03	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur hemmung der expression des huntingtin-gens
US20100069461A1 (en)	2005-11-09	2010-03-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2007062380A2 (en)	2005-11-21	2007-05-31	Isis Pharmaceuticals, Inc.	Modulation of eif4e-bp2 expression
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
JP2009524411A (ja) *	2005-12-21	2009-07-02	イェールユニバーシティー	リボスイッチの調節に関連した方法および組成物
EP1976567B1 (de)	2005-12-28	2020-05-13	The Scripps Research Institute	Natürliche antisense- und nicht-kodierende rna-transkripte als arzneitargets
CA2637267A1 (en)	2006-01-16	2007-07-19	Compugen Ltd.	Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
DK2314594T3 (da) *	2006-01-27	2014-10-27	Isis Pharmaceuticals Inc	6-modificerede bicykliske nukleinsyreanaloger
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
AU2007211082B2 (en)	2006-01-27	2012-09-27	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of microRNAs
WO2007115168A2 (en)	2006-03-31	2007-10-11	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of eg5 gene
DE102006020885A1 (de) *	2006-05-05	2007-11-08	Qiagen Gmbh	Einführung von Sequenzelementen in Nukleinsäuren
CA3044969A1 (en) *	2006-05-05	2007-12-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating gene expression
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
NZ572666A (en)	2006-05-11	2010-11-26	Alnylam Pharmaceuticals Inc	Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene
CA2651453C (en)	2006-05-11	2014-10-14	Isis Pharmaceuticals, Inc.	5'-modified bicyclic nucleic acid analogs
EP2023937B1 (de)	2006-05-19	2011-10-12	Alnylam Pharmaceuticals Inc.	Rnai-modulation von aha und ihre therapeutische verwendung
WO2007137220A2 (en)	2006-05-22	2007-11-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of ikk-b gene
WO2008011473A2 (en)	2006-07-19	2008-01-24	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to hbxip
US20100137440A1 (en) *	2006-09-11	2010-06-03	Yale University	Lysine riboswitches, structure-based compound design with lysine riboswitches, and methods and compositions for use of and with lysine riboswitches
US20090209478A1 (en)	2006-09-21	2009-08-20	Tomoko Nakayama	Compositions and methods for inhibiting expression of the hamp gene
WO2008036825A2 (en)	2006-09-22	2008-03-27	Dharmacon, Inc.	Duplex oligonucleotide complexes and methods for gene silencing by rna interference
AU2007303205A1 (en)	2006-10-03	2008-04-10	Tekmira Pharmaceuticals Corporation	Lipid containing formulations
US20100166743A1 (en)	2006-10-06	2010-07-01	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
WO2008136852A2 (en)	2006-11-01	2008-11-13	University Of Rochester	Methods and compositions related to the structure and function of apobec3g
BRPI0720038A2 (pt)	2006-12-11	2013-12-24	Univ Utah Res Found	Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor
WO2008094370A2 (en)	2006-12-22	2008-08-07	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
CA2675967A1 (en) *	2007-01-16	2008-07-24	Yissum Research Development Company Of The Hebrew University Of Jerusale M	Nucleic acid constructs and methods for specific silencing of h19
US20100196403A1 (en) *	2007-01-29	2010-08-05	Jacob Hochman	Antibody conjugates for circumventing multi-drug resistance
US8507200B2 (en) *	2007-02-09	2013-08-13	Northwestern University	Particles for detecting intracellular targets
EP2471925A1 (de)	2007-03-22	2012-07-04	Yale University	Verfahren und Zusammensetzungen für Riboswitches, die das alternative Spleissen kontrollieren
PE20090064A1 (es)	2007-03-26	2009-03-02	Novartis Ag	Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
WO2008121604A2 (en)	2007-03-29	2008-10-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a gene from the ebola
WO2008141275A1 (en)	2007-05-11	2008-11-20	The Johns Hopkins University	Biomarkers for melanoma
CA2687684A1 (en) *	2007-05-29	2008-12-11	Yale University	Methods and compositions related to riboswitches that control alternative splicing and rna processing
US20100286082A1 (en) *	2007-05-29	2010-11-11	Yale University	Riboswitches and methods and compositions for use of and with riboswitches
EP2170917B1 (de)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	Über n-substituiertes aminomethylen verbrückte, bicyclische nukleinsäureanaloga
WO2008151049A2 (en)	2007-05-30	2008-12-11	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
WO2008154401A2 (en)	2007-06-08	2008-12-18	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
EP2164966A2 (de)	2007-07-05	2010-03-24	Novartis Ag	Dsrna zur behandlung von virusinfektionen
CA2692579C (en) *	2007-07-05	2016-05-03	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
KR101654007B1 (ko)	2007-08-15	2016-09-05	아이오니스 파마수티컬즈, 인코포레이티드	테트라하이드로피란 핵산 유사체
AU2008296487A1 (en)	2007-08-28	2009-03-12	The Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
DK2682400T5 (da)	2007-08-28	2017-11-27	Uab Research Foundation	Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
PT2769729T (pt)	2007-09-04	2019-05-08	Compugen Ltd	Polipéptidos e polinucleótidos, e utilizações dos mesmos como um alvo de fármacos para produzir fármacos e agentes biológicos
WO2009039466A1 (en)	2007-09-20	2009-03-26	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
WO2009039442A1 (en) *	2007-09-21	2009-03-26	California Institute Of Technology	Nfia in glial fate determination, glioma therapy and astrocytoma treatment
CA2700953A1 (en)	2007-10-02	2009-04-09	Amgen Inc.	Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
WO2009060124A2 (en) *	2007-11-05	2009-05-14	Baltic Technology Development, Ltd.	Use of oligonucleotides with modified bases in hybridization of nucleic acids
US8097712B2 (en)	2007-11-07	2012-01-17	Beelogics Inc.	Compositions for conferring tolerance to viral disease in social insects, and the use thereof
USRE47320E1 (en)	2007-11-20	2019-03-26	Ionis Pharmaceuticals, Inc.	Modulation of CD40 expression
US8546556B2 (en) *	2007-11-21	2013-10-01	Isis Pharmaceuticals, Inc	Carbocyclic alpha-L-bicyclic nucleic acid analogs
EP2245159A2 (de)	2007-12-10	2010-11-03	Alnylam Pharmaceuticals Inc.	Zusammensetzungen und verfahren zur hemmung der expression des faktor-vii-gens
EP3100718B1 (de)	2008-01-02	2019-11-27	Arbutus Biopharma Corporation	Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
EP2265627A2 (de) *	2008-02-07	2010-12-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexitolnukleinsäureanaloga
US8188060B2 (en)	2008-02-11	2012-05-29	Dharmacon, Inc.	Duplex oligonucleotides with enhanced functionality in gene regulation
CA2715289C (en) *	2008-02-11	2019-12-24	Rxi Pharmaceuticals Corporation	Modified rnai polynucleotides and uses thereof
WO2009111658A2 (en)	2008-03-05	2009-09-11	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of eg5 and vegf genes
WO2009117589A1 (en)	2008-03-21	2009-09-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucleosides and methods for their use
EP2285819B1 (de) *	2008-04-04	2013-10-16	Isis Pharmaceuticals, Inc.	Oligomere verbindungen, die neutral gebundene, terminal bicyclische nukleoside enthalten
EP2982753B1 (de)	2008-04-18	2018-06-06	Baxter International Inc.	Zusammensetzung auf mikrokügelchenbasis zur vorbeugung und/oder abwendung einer neuerkrankung an autoimmunem diabetes
EP2280995A2 (de) *	2008-04-29	2011-02-09	Wyeth LLC	Verfahren zur behandlung von entzündungen
US8082730B2 (en) *	2008-05-20	2011-12-27	Caterpillar Inc.	Engine system having particulate reduction device and method
KR20110017005A (ko) *	2008-07-15	2011-02-18	에프. 호프만-라 로슈 아게	Ｔｇｆ-베타 수용체 유전자 발현 억제용 조성물 및 방법
US8815818B2 (en)	2008-07-18	2014-08-26	Rxi Pharmaceuticals Corporation	Phagocytic cell delivery of RNAI
EP2323667A4 (de) *	2008-08-07	2012-07-25	Isis Pharmaceuticals Inc	Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
EP3081648A1 (de)	2008-08-25	2016-10-19	Excaliard Pharmaceuticals, Inc.	Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
US8318693B2 (en)	2008-09-02	2012-11-27	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mutant EGFR gene
US8796443B2 (en)	2008-09-22	2014-08-05	Rxi Pharmaceuticals Corporation	Reduced size self-delivering RNAi compounds
WO2010036696A1 (en) *	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acid analogs
EP2356129B1 (de) *	2008-09-24	2013-04-03	Isis Pharmaceuticals, Inc.	Substituierte alpha-l-bicyclische nukleoside
EP3109321B1 (de)	2008-09-25	2019-05-01	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
US9139554B2 (en)	2008-10-09	2015-09-22	Tekmira Pharmaceuticals Corporation	Amino lipids and methods for the delivery of nucleic acids
AU2009305636A1 (en)	2008-10-15	2010-04-22	Ionis Pharmaceuticals, Inc.	Modulation of Factor 11 expression
NO2937418T3 (de)	2008-10-20	2018-03-17
CA2741294C (en)	2008-10-24	2018-04-24	Isis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
US8987435B2 (en)	2008-10-24	2015-03-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
SG171737A1 (en) *	2008-11-17	2011-07-28	Hoffmann La Roche	Compositions and methods for inhibiting expression of factor vii genes
WO2010059226A2 (en)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition of map4k4 through rnai
MX2011005429A (es) *	2008-11-24	2011-06-21	Univ Northwestern	Composiciones de nanoparticulas de arn polivalentes.
WO2010061393A1 (en)	2008-11-30	2010-06-03	Compugen Ltd.	He4 variant nucleotide and amino acid sequences, and methods of use thereof
EP2370580B1 (de)	2008-12-04	2019-09-11	CuRNA, Inc.	Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirtuin 1
CN102317458B (zh)	2008-12-04	2018-01-02	库尔纳公司	通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
RU2746478C2 (ru)	2008-12-04	2021-04-14	КьюРНА, Инк.	Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
EP2633854B1 (de)	2008-12-05	2015-09-16	Yeda Research And Development Co. Ltd.	miRNA-9 or miRNA-9* zur Verwendung in der Behandlung von ALS
CA2746514C (en)	2008-12-10	2018-11-27	Alnylam Pharmaceuticals, Inc.	Gnaq targeted dsrna compositions and methods for inhibiting expression
EP2376633A1 (de)	2008-12-17	2011-10-19	AVI BioPharma, Inc.	Antisense-zusammensetzungen und verfahren zur modulation von kontaktüberempfindlichkeit oder kontaktdermatitis
US20100184844A1 (en) *	2009-01-08	2010-07-22	Northwestern University	Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
US20100233270A1 (en) *	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
EP3243504A1 (de)	2009-01-29	2017-11-15	Arbutus Biopharma Corporation	Verbesserte lipidformulierung
SG173182A1 (en) *	2009-02-03	2011-09-29	Hoffmann La Roche	Compositions and methods for inhibiting expression of ptp1b genes
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
CN102439149B (zh)	2009-02-12	2018-01-02	库尔纳公司	通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
PT2396038E (pt)	2009-02-12	2016-02-19	Curna Inc	Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
EP2403863B1 (de)	2009-03-02	2013-08-28	Alnylam Pharmaceuticals Inc.	Chemische modifikationen von nukleinsäure
CA2754749C (en)	2009-03-04	2019-04-30	Opko Curna, Llc	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
NZ594995A (en)	2009-03-12	2013-06-28	Alnylam Pharmaceuticals Inc	LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
ES2656290T3 (es)	2009-03-16	2018-02-26	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
EP2408920B1 (de)	2009-03-17	2017-03-08	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
WO2010120420A1 (en)	2009-04-15	2010-10-21	Northwestern University	Delivery of oligonucleotide-functionalized nanoparticles
EP3248618A1 (de)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
CA2760589C (en)	2009-05-01	2019-08-20	Joseph Collard	Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
NZ621981A (en)	2009-05-05	2015-09-25	Tekmira Pharmaceuticals Corp	Lipid compositions
CA3045126A1 (en)	2009-05-05	2010-11-11	Arbutus Biopharma Corporation	Methods of delivering oligonucleotides to immune cells
KR101722541B1 (ko)	2009-05-06	2017-04-04	큐알엔에이, 인크.	Ｔｔｐ에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
CN103223177B (zh)	2009-05-06	2016-08-10	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
EP2430161A1 (de)	2009-05-15	2012-03-21	Yale University	Gemm-riboswitches, strukturbasierte verbindungskonstruktion mit gemm-riboswitches sowie verfahren und zusammensetzungen zur verwendung von und mit gemm-riboswitches
EP2429657A2 (de) *	2009-05-15	2012-03-21	F. Hoffmann-La Roche AG	Zusammensetzungen und verfahren zu unterdrückung der expression von glukokortikoid-rezeptor (gcr)-genen
CA2762369C (en)	2009-05-18	2021-12-28	Joseph Collard	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
EP2432882B1 (de)	2009-05-22	2019-12-25	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
US20100303795A1 (en) *	2009-05-27	2010-12-02	Soerensen Karina Dalsgaard	Marker of prostate cancer
CA2764683A1 (en)	2009-05-28	2010-12-02	Joseph Collard	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
HUE056773T2 (hu)	2009-06-10	2022-03-28	Arbutus Biopharma Corp	Továbbfejlesztett lipid készítmény
JP6128846B2 (ja)	2009-06-16	2017-05-17	クルナ・インコーポレーテッド	パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
EP2443237B1 (de)	2009-06-16	2017-02-22	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit dem kollagengen durch hemmung des natürlichen antisense-transkripts zu einem kollagengens
CN102597238B (zh)	2009-06-24	2016-06-29	库尔纳公司	通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病
US20100331397A1 (en) *	2009-06-24	2010-12-30	Alios Biopharma, Inc.	2-5a analogs and their methods of use
CN102482672B (zh)	2009-06-26	2016-11-09	库尔纳公司	通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
WO2011005861A1 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	Oligonucleotide end caps
WO2011005860A2 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	5' phosphate mimics
CN102762731B (zh)	2009-08-05	2018-06-22	库尔纳公司	通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
EP2462153B1 (de)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexosenukleinsäureanaloga
AP3574A (en)	2009-08-14	2016-02-08	Alnylam Pharmaceuticals Inc	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en)	2009-08-17	2012-06-21	Yale University	Methylation biomarkers and methods of use
JP5964232B2 (ja)	2009-08-25	2016-08-03	カッパーアールエヌエー，インコーポレイテッド	‘ｉｑモチーフ含有ｇｔｐアーゼ活性化タンパク質’（ｉｑｇａｐ）に対する天然アンチセンス転写産物の阻害によるｉｑｇａｐ関連疾患の治療
JP5887270B2 (ja)	2009-09-02	2016-03-16	ジェネンテック，インコーポレイテッド	突然変異体ｓｍｏｏｔｈｅｎｅｄおよびその使用方法
WO2011044902A1 (en)	2009-10-13	2011-04-21	Aarhus Universitet	Tff3 hypomethylation as a novel biomarker for prostate cancer
US8962584B2 (en)	2009-10-14	2015-02-24	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Compositions for controlling Varroa mites in bees
EP2488646B1 (de)	2009-10-14	2017-12-06	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Zusammensetzungen zur steuerung vpn varroa-milben bei bienen
RU2539772C2 (ru)	2009-10-22	2015-01-27	Дженентек, Инк.	Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
JP6147502B2 (ja)	2009-10-27	2017-06-14	スウィフトバイオサイエンシーズ，インコーポレイテッド	ポリヌクレオチドプライマー及びプローブ
EP2494075B1 (de)	2009-10-30	2018-04-04	Northwestern University	Templatgesteuerte nanokonjugate
AU2010315867A1 (en)	2009-11-03	2012-06-21	University Of Virginia Patent Foundation	Versatile, visible method for detecting polymeric analytes
WO2011054939A2 (en)	2009-11-09	2011-05-12	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of kif10 genes
WO2011058555A1 (en)	2009-11-12	2011-05-19	Yeda Research And Development Co. Ltd.	A method of editing dna in a cell and constructs capable of same
KR101944119B1 (ko)	2009-11-13	2019-01-30	사렙타 쎄러퓨틱스 인코퍼레이티드	안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법
CA2781469A1 (en)	2009-11-23	2011-05-26	Swift Biosciences, Inc.	Devices to extend single stranded target molecules
CN103755809B (zh)	2009-11-30	2016-06-01	霍夫曼-拉罗奇有限公司	治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
KR101823702B1 (ko)	2009-12-16	2018-01-30	큐알엔에이, 인크.	막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료
JP6031356B2 (ja)	2009-12-23	2016-11-24	カッパーアールエヌエー，インコーポレイテッド	Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
US8940708B2 (en)	2009-12-23	2015-01-27	Curna, Inc.	Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
CA2785177C (en)	2009-12-29	2019-09-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
CN102782134B (zh)	2009-12-29	2017-11-24	库尔纳公司	通过抑制核呼吸因子1(nrf1)的天然反义转录物而治疗nrf1相关疾病
WO2011082409A2 (en)	2010-01-04	2011-07-07	Curna, Inc.	Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2011085066A2 (en)	2010-01-06	2011-07-14	Curna, Inc.	Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US8779118B2 (en)	2010-01-11	2014-07-15	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2524039B1 (de)	2010-01-11	2017-11-29	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit dem sexualhormonbindenden globulin (shgb) mittels hemmung des natürlichen antisense-transkripts gegen shbg
US20120321647A1 (en)	2010-01-12	2012-12-20	Yale University	Structured rna motifs and compounds and methods for their use
RU2611192C2 (ru)	2010-01-25	2017-02-21	Курна, Инк.	ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
WO2011097407A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
WO2011095174A1 (en)	2010-02-08	2011-08-11	Aarhus Universitet	Human herpes virus 6 and 7 u20 polypeptide and polynucleotides for use as a medicament or diagnosticum
US8962586B2 (en)	2010-02-22	2015-02-24	Curna, Inc.	Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
AR080243A1 (es)	2010-02-23	2012-03-21	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011107100A1 (en)	2010-03-03	2011-09-09	Aarhus Universitet	Methods and compositions for regulation of herv4
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
CA2790211C (en)	2010-03-08	2020-06-09	Monsanto Technology Llc	Methods and compositions for delivering polynucleotides into plants
US9068185B2 (en)	2010-03-12	2015-06-30	Sarepta Therapeutics, Inc.	Antisense modulation of nuclear hormone receptors
US20130101512A1 (en)	2010-03-12	2013-04-25	Chad A. Mirkin	Crosslinked polynucleotide structure
EP2544703A4 (de)	2010-03-12	2013-09-18	Brigham & Womens Hospital	Verfahren zur behandlung von gefässentzündungserkrankungen
US9193752B2 (en)	2010-03-17	2015-11-24	Isis Pharmaceuticals, Inc.	5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
US9080171B2 (en)	2010-03-24	2015-07-14	RXi Parmaceuticals Corporation	Reduced size self-delivering RNAi compounds
WO2011119871A1 (en)	2010-03-24	2011-09-29	Rxi Phrmaceuticals Corporation	Rna interference in ocular indications
EP2550002B1 (de)	2010-03-24	2019-05-08	Phio Pharmaceuticals Corp.	Rna-interferenz bei dermalen und fibrotischen erkrankungen
WO2011120046A2 (en)	2010-03-26	2011-09-29	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
AU2011235276B2 (en)	2010-03-29	2015-09-03	Alnylam Pharmaceuticals, Inc.	SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
WO2011123621A2 (en)	2010-04-01	2011-10-06	Alnylam Pharmaceuticals Inc.	2' and 5' modified monomers and oligonucleotides
TWI644675B (zh)	2010-04-09	2018-12-21	可娜公司	藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
WO2011133695A2 (en)	2010-04-20	2011-10-27	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
US9725479B2 (en)	2010-04-22	2017-08-08	Ionis Pharmaceuticals, Inc.	5′-end derivatives
WO2011139699A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
US8993738B2 (en)	2010-04-28	2015-03-31	Isis Pharmaceuticals, Inc.	Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
BR112012027547B1 (pt)	2010-04-29	2022-06-14	Ionis Pharmaceuticals, Inc	Oligonucleotídeo modificado de fita simples, composição, e seus usos para tratar amiloidose transtirretina, reduzir os seus sintomas e para reduzir a expressão de mrna ou de proteína de transtirretina
SG185027A1 (en)	2010-05-03	2012-11-29	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
KR101915115B1 (ko)	2010-05-03	2018-11-05	큐알엔에이, 인크.	시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
CA3090304A1 (en)	2010-05-13	2011-11-17	Sarepta Therapeutics, Inc.	Antisense modulation of interleukins 17 and 23 signaling
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US20130203045A1 (en)	2010-05-26	2013-08-08	University Of Virginia Patent Foundation	Method for detecting nucleic acids based on aggregate formation
US8895528B2 (en)	2010-05-26	2014-11-25	Curna, Inc.	Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
EP2576579B1 (de)	2010-06-02	2018-08-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von leberfibrose
WO2011156278A1 (en)	2010-06-07	2011-12-15	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8846637B2 (en)	2010-06-08	2014-09-30	Isis Pharmaceuticals, Inc.	Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156713A1 (en)	2010-06-11	2011-12-15	Vanderbilt University	Multiplexed interferometric detection system and method
US9168297B2 (en)	2010-06-23	2015-10-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (NRG-1)
EP3202415B1 (de)	2010-06-30	2021-12-08	Compugen Ltd.	Fusionsprotein beinhaltend c1orf32 und eine oder mehrere domänen einer immunoglobulin heavy chain konstanten region zur behandlung von multipler sklerose, rheumatoider arthritis und anderen autoimmunerkrankungen
US8980860B2 (en)	2010-07-14	2015-03-17	Curna, Inc.	Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
US20130143955A1 (en)	2010-08-09	2013-06-06	Yale University	Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
WO2012038956A1 (en)	2010-09-20	2012-03-29	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Method of treating neurodegenerative diseases
EP2625197B1 (de)	2010-10-05	2016-06-29	Genentech, Inc.	Smoothened-mutant und verfahren zu seiner anwendung
CN103210086B (zh)	2010-10-06	2017-06-09	库尔纳公司	通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
CN103517990A (zh)	2010-10-07	2014-01-15	通用医疗公司	癌症生物标志物
WO2012052872A2 (en)	2010-10-17	2012-04-26	Yeda Research And Development Co. Ltd.	Methods and compositions for the treatment of insulin-associated medical conditions
EP3434772A3 (de)	2010-10-18	2019-03-20	Arrowhead Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
EP2630241B1 (de)	2010-10-22	2018-10-17	CuRNA, Inc.	Behandlung von alpha-l-iduronidase (idua)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen idua
JP6073795B2 (ja)	2010-10-27	2017-02-01	カッパーアールエヌエー，インコーポレイテッド	インターフェロン関連発生制御因子１（ｉｆｒｄ１）への天然アンチセンス転写物の阻害によるｉｆｒｄ１関連疾患の治療
CN110123830A (zh)	2010-11-09	2019-08-16	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
GB201019043D0 (en)	2010-11-10	2010-12-22	Protea Biopharma N V	Use of 2',5'-oligoadenylate derivative compounds
EP2638163B1 (de)	2010-11-12	2017-05-17	The General Hospital Corporation	Polycomb-assoziierte nicht-kodierende rnas
AU2011329777B2 (en)	2010-11-17	2016-06-09	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
KR102010598B1 (ko)	2010-11-23	2019-08-13	큐알엔에이, 인크.	Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
EP2649182A4 (de)	2010-12-10	2015-05-06	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
WO2012079046A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
US9045749B2 (en)	2011-01-14	2015-06-02	The General Hospital Corporation	Methods targeting miR-128 for regulating cholesterol/lipid metabolism
KR101697396B1 (ko)	2011-02-02	2017-01-17	엑스칼리아드 파마슈티컬즈, 인코포레이티드	결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
EP2670404B1 (de)	2011-02-02	2018-08-29	The Trustees of Princeton University	Sirtuin-modulatoren als modulatoren der virusproduktion
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
MX360349B (es)	2011-03-29	2018-10-30	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
WO2012138453A1 (en)	2011-04-03	2012-10-11	The General Hospital Corporation	Efficient protein expression in vivo using modified rna (mod-rna)
EP2697256A1 (de)	2011-04-15	2014-02-19	Compugen Ltd.	Polypeptide und polynukleotide sowie ihre verwendung zur behandlung von immunerkrankungen und krebs
WO2012149154A1 (en)	2011-04-26	2012-11-01	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2838588C (en)	2011-06-09	2021-09-14	Curna, Inc.	Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
EP2723756B1 (de)	2011-06-21	2020-03-11	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression von apolipoprotein-c-iii (apoc3)-genen
EP2723351B1 (de)	2011-06-21	2018-02-14	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
SG10201800715PA (en)	2011-06-21	2018-02-27	Alnylam Pharmaceuticals Inc	Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
US20140235693A1 (en)	2011-06-23	2014-08-21	Alnylam Pharmaceuticals, Inc.	Serpina1 sirnas: compositions of matter and methods of treatment
AU2012277376B2 (en)	2011-06-30	2016-11-24	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EA202191537A1 (ru)	2011-06-30	2022-01-31	Эрроухэд Фармасьютикалс, Инк.	Композиции и способы ингибирования экспрессии генов вируса гепатита в
US20140328811A1 (en)	2011-08-01	2014-11-06	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
EP2739736B1 (de)	2011-08-04	2017-04-19	Yeda Research and Development Co. Ltd.	Mir-135 und zusammensetzungen damit zur behandlung von serotonin vermittelten medizinischen leiden
US9840715B1 (en)	2011-09-13	2017-12-12	Monsanto Technology Llc	Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10829828B2 (en)	2011-09-13	2020-11-10	Monsanto Technology Llc	Methods and compositions for weed control
MX343072B (es)	2011-09-13	2016-10-21	Monsanto Technology Llc	Metodos y composiciones para controlar malezas.
BR112014005975A8 (pt)	2011-09-13	2017-09-12	Monsanto Technology Llc	Método de controle de planta, método de redução de expressão de um gene pds em uma planta, cassete de expressão microbiana, método de fazer um polinucleotídeo, método de identificação de polinucleotídeos, e composições para controle de erva daninha
US10806146B2 (en)	2011-09-13	2020-10-20	Monsanto Technology Llc	Methods and compositions for weed control
US10760086B2 (en)	2011-09-13	2020-09-01	Monsanto Technology Llc	Methods and compositions for weed control
MX343071B (es)	2011-09-13	2016-10-21	Monsanto Technology Llc	Metodos y composiciones para el control de malezas.
EP2755467B1 (de)	2011-09-13	2017-07-19	Monsanto Technology LLC	Verfahren und zusammensetzungen zur unkrautbekämpfung
US9920326B1 (en)	2011-09-14	2018-03-20	Monsanto Technology Llc	Methods and compositions for increasing invertase activity in plants
JP6129844B2 (ja)	2011-09-14	2017-05-17	ラナセラピューティクスインコーポレイテッド	多量体オリゴヌクレオチド化合物
CA2847698C (en)	2011-09-14	2020-09-01	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
US9580713B2 (en)	2011-09-17	2017-02-28	Yale University	Fluoride-responsive riboswitches, fluoride transporters, and methods of use
AU2012322788B2 (en)	2011-10-11	2018-01-04	The Brigham And Women's Hospital, Inc.	Micrornas in neurodegenerative disorders
KR102102862B1 (ko)	2011-10-14	2020-04-22	제넨테크, 인크.	항-HtrA1 항체 및 사용 방법
FR2981650B1 (fr) *	2011-10-24	2013-12-27	Univ Paris Curie	Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement
US9145559B2 (en)	2011-10-27	2015-09-29	Yeda Research And Development Co. Ltd.	Methods of treating cancer
DK2790736T3 (en)	2011-12-12	2018-05-07	Oncoimmunin Inc	In vivo delivery of oligonucleotides
MX2014009289A (es)	2012-02-01	2015-09-08	Compugen Ltd	Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
SG11201404608WA (en)	2012-02-13	2014-09-26	Gamida Cell Ltd	Mesenchymal stem cells conditioned medium and methods of generating and using the same
EP3401393B1 (de)	2012-02-22	2020-02-19	Exostem Biotec Ltd	Mikrornas zur erzeugung von astrocyten
EP2844745A2 (de)	2012-02-22	2015-03-11	Brainstem Biotec Ltd.	Erzeugung von neuralen stammzellen und motorneuronen
WO2013138536A1 (en)	2012-03-13	2013-09-19	Swift Biosciences, Inc.	Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
KR20140136488A (ko)	2012-03-15	2014-11-28	큐알엔에이, 인크.	뇌 유래 신경영양 인자（ｂｄｎｆ）에 대한 천연 안티센스 전사체의 저해에 의한 뇌 유래 신경영양 인자（ｂｄｎｆ）관련 질환의 치료
WO2013138662A1 (en)	2012-03-16	2013-09-19	4S3 Bioscience, Inc.	Antisense conjugates for decreasing expression of dmpk
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9221864B2 (en)	2012-04-09	2015-12-29	Isis Pharmaceuticals, Inc.	Tricyclic nucleic acid analogs
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
AU2013248981B2 (en)	2012-04-20	2018-11-29	Aptamir Therapeutics, Inc.	Mirna modulators of thermogenesis
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
KR102028784B1 (ko)	2012-05-16	2019-10-04	트랜슬레이트 바이오 인코포레이티드	유전자 발현을 조절하기 위한 조성물 및 방법
CN104583402A (zh)	2012-05-16	2015-04-29	Rana医疗有限公司	用于调节mecp2表达的组合物和方法
SG11201407483YA (en)	2012-05-16	2014-12-30	Rana Therapeutics Inc	Compositions and methods for modulating smn gene family expression
AU2013264742B2 (en)	2012-05-24	2018-10-04	A.B. Seeds Ltd.	Compositions and methods for silencing gene expression
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
CA2880833A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
KR102237882B1 (ko)	2012-08-15	2021-04-07	아이오니스 파마수티컬즈, 인코포레이티드	변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
CA2880869A1 (en)	2012-08-20	2014-02-27	The Regents Of The University Of California	Polynucleotides having bioreversible groups
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CN104870647A (zh)	2012-10-18	2015-08-26	孟山都技术公司	用于植物害虫控制的方法和组合物
CA3201145A1 (en)	2012-10-26	2014-05-01	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
CA2890207A1 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel ntrk1 fusion molecules and uses thereof
US10683505B2 (en)	2013-01-01	2020-06-16	Monsanto Technology Llc	Methods of introducing dsRNA to plant seeds for modulating gene expression
WO2014106837A2 (en)	2013-01-01	2014-07-10	A. B. Seeds Ltd.	ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
EP2945652B1 (de)	2013-01-18	2021-07-07	Foundation Medicine, Inc.	Verfahren zur behandlung cholangiokarzinom
US10000767B2 (en)	2013-01-28	2018-06-19	Monsanto Technology Llc	Methods and compositions for plant pest control
US9701708B2 (en)	2013-01-31	2017-07-11	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified coupling protocols
JP6613143B2 (ja) *	2013-02-22	2019-11-27	サーナ・セラピューティクス・インコーポレイテッド	２’ヌクレオシド間結合を含有する低分子干渉核酸（ｓｉＮＡ）分子
WO2014130922A1 (en)	2013-02-25	2014-08-28	Trustees Of Boston University	Compositions and methods for treating fungal infections
AR095233A1 (es)	2013-03-13	2015-09-30	Monsanto Technology Llc	Métodos y composiciones para el control de malezas
CA2905027A1 (en)	2013-03-13	2014-10-09	Monsanto Technology Llc	Methods and compositions for weed control
KR20230162998A (ko)	2013-03-14	2023-11-29	알닐람 파마슈티칼스 인코포레이티드	보체 성분 Ｃ5 ｉＲＮＡ 조성물 및 그 이용 방법
US20140283211A1 (en)	2013-03-14	2014-09-18	Monsanto Technology Llc	Methods and Compositions for Plant Pest Control
US10568328B2 (en)	2013-03-15	2020-02-25	Monsanto Technology Llc	Methods and compositions for weed control
CN115261411A (zh)	2013-04-04	2022-11-01	哈佛学院校长同事会	利用CRISPR/Cas系统的基因组编辑的治疗性用途
EP3633039A1 (de)	2013-05-01	2020-04-08	Ionis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren
HUE038146T2 (hu)	2013-05-22	2018-09-28	Alnylam Pharmaceuticals Inc	Serpina1 IRNS készítmények és eljárások alkalmazásukra
KR102365809B1 (ko)	2013-05-22	2022-02-23	알닐람 파마슈티칼스 인코포레이티드	Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
US20160113911A1 (en)	2013-06-06	2016-04-28	The General Hospital Corporation	Methods and compositions for the treatment of cancer
WO2014197938A1 (en)	2013-06-13	2014-12-18	Antisense Therapeutics Ltd	Combination therapy
EP3030663B1 (de)	2013-07-19	2019-09-04	Monsanto Technology LLC	Zusammensetzungen und verfahren zur bekämpfung von leptinotarsa
US9850496B2 (en)	2013-07-19	2017-12-26	Monsanto Technology Llc	Compositions and methods for controlling Leptinotarsa
AU2014292926B2 (en)	2013-07-25	2020-03-05	Exicure Operating Company	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
HUE048710T2 (hu)	2013-08-08	2020-08-28	Scripps Research Inst	Eljárás nukleinsavak in vitro helyspecifikus enzimes jelölésére nem-természetes nukleotidok beépítésével
EP3052512A4 (de)	2013-09-30	2017-02-22	Geron Corporation	Phosphorodiamidat-rückgratverbindung für oligonukleotide
EP3052626A1 (de)	2013-10-02	2016-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
EP3052464B1 (de)	2013-10-04	2020-04-15	Novartis AG	3 endkappen für rnai-mittel zur verwendung in der rna-interferenz
US9988627B2 (en)	2013-10-04	2018-06-05	Novartis Ag	Formats for organic compounds for use in RNA interference
PE20161130A1 (es)	2013-10-04	2016-11-25	Icahn School Med Mount Sinai	Composiciones y metodos para inhibir la expresion del gen alas1
WO2015050871A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Organic compounds to treat hepatitis b virus
WO2015054451A1 (en)	2013-10-09	2015-04-16	The United States Of America As Represented By The Secretary Department Of Health And Human Services	Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
JP2016536303A (ja)	2013-10-21	2016-11-24	ザジェネラルホスピタルコーポレイション	末梢循環腫瘍細胞クラスターおよび癌処置に関する方法
US9758546B2 (en)	2013-10-21	2017-09-12	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
WO2015066708A1 (en)	2013-11-04	2015-05-07	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
US9540642B2 (en)	2013-11-04	2017-01-10	The United States Of America, As Represented By The Secretary Of Agriculture	Compositions and methods for controlling arthropod parasite and pest infestations
US10934550B2 (en)	2013-12-02	2021-03-02	Phio Pharmaceuticals Corp.	Immunotherapy of cancer
CA2932122C (en)	2013-12-03	2022-04-19	Northwestern University	Liposomal particles, methods of making same and uses thereof
US10385388B2 (en)	2013-12-06	2019-08-20	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
UA119253C2 (uk)	2013-12-10	2019-05-27	Біолоджикс, Інк.	Спосіб боротьби із вірусом у кліща varroa та у бджіл
AU2014362262B2 (en)	2013-12-12	2021-05-13	Alnylam Pharmaceuticals, Inc.	Complement component iRNA compositions and methods of use thereof
CA2934344A1 (en)	2013-12-20	2015-06-25	David T. TING	Methods and assays relating to circulating tumor cells
AU2015206585A1 (en)	2014-01-15	2016-07-21	Monsanto Technology Llc	Methods and compositions for weed control using EPSPS polynucleotides
CA2937539A1 (en)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened and methods of using the same
US10125365B2 (en)	2014-02-05	2018-11-13	Yeda Research And Development Co. Ltd.	Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
CA2938857A1 (en)	2014-02-11	2015-08-20	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
CA2942340A1 (en)	2014-03-19	2015-09-24	Ionis Pharmaceuticals, Inc.	Compositions for modulating ataxin 2 expression
US10006027B2 (en)	2014-03-19	2018-06-26	Ionis Pharmaceuticals, Inc.	Methods for modulating Ataxin 2 expression
SG10201906520RA (en)	2014-04-01	2019-09-27	Biogen Ma Inc	Compositions for modulating sod-1 expression
EP3420809A1 (de)	2014-04-01	2019-01-02	Monsanto Technology LLC	Zusammensetzungen und verfahren zur bekämpfung von insektenbefall
WO2015157555A2 (en)	2014-04-09	2015-10-15	The Scripps Research Institute	Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
WO2015164693A1 (en)	2014-04-24	2015-10-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
US11279934B2 (en)	2014-04-28	2022-03-22	Phio Pharmaceuticals Corp.	Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
US10098959B2 (en)	2014-05-01	2018-10-16	Ionis Pharmaceuticals, Inc.	Method for synthesis of reactive conjugate clusters
PE20170010A1 (es)	2014-05-01	2017-03-04	Ionis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion del factor b del complemento
WO2015175510A1 (en)	2014-05-12	2015-11-19	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating a serpinc1-associated disorder
JP6811094B2 (ja)	2014-05-22	2021-01-13	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	アンジオテンシノーゲン（ＡＧＴ）ｉＲＮＡ組成物およびその使用
US10456445B2 (en)	2014-06-02	2019-10-29	Children's Medical Center Corporation	Methods and compositions for immunomodulation
TR201908550T4 (tr)	2014-06-04	2019-07-22	Exicure Inc	Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
CN106661580B (zh)	2014-06-10	2022-02-15	鹿特丹伊拉斯谟大学医疗中心	用于治疗庞帕病的反义寡核苷酸
WO2015200223A1 (en)	2014-06-23	2015-12-30	Monsanto Technology Llc	Compositions and methods for regulating gene expression via rna interference
EP3161138A4 (de)	2014-06-25	2017-12-06	Monsanto Technology LLC	Verfahren und zusammensetzungen zur zuführung von nukleinsäuren an pflanzenzellen und regulierung der genexpression
WO2015200697A1 (en)	2014-06-25	2015-12-30	The General Hospital Corporation	Targeting human satellite ii (hsatii)
BR112017000710B1 (pt)	2014-07-15	2024-02-27	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Polipeptídeo isolado, composição de matéria, e, uso do polipeptídeo isolado ou da composição da matéria
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
WO2016018887A1 (en)	2014-07-29	2016-02-04	Monsanto Technology Llc	Compositions and methods for controlling insect pests
MX2017001432A (es)	2014-07-31	2017-05-09	Uab Res Found	Peptidos mimeticos de la apoe y mayor potencia para depurar el colesterol en plasma.
EP3183007B1 (de)	2014-08-19	2020-06-17	Northwestern University	Therapeutika mit protein/oligonukleotid-kernschalennanopartikeln
WO2016030899A1 (en)	2014-08-28	2016-03-03	Yeda Research And Development Co. Ltd.	Methods of treating amyotrophic lateral scleroses
EP3185957B1 (de)	2014-08-29	2022-06-01	Alnylam Pharmaceuticals, Inc.	Patisiran zur behandlung von transthyretin-vermittelter amyloidose
JP2017526367A (ja)	2014-08-29	2017-09-14	チルドレンズメディカルセンターコーポレーション	癌の処置のための方法および組成物
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
CN107073294A (zh)	2014-09-05	2017-08-18	阿克赛医药公司	使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
WO2016040589A1 (en)	2014-09-12	2016-03-17	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
EP3198012B1 (de)	2014-09-26	2019-09-04	University of Massachusetts	Rna-modulierende stoffe
JOP20200115A1 (ar)	2014-10-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
WO2016069694A2 (en)	2014-10-30	2016-05-06	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
CN113846101A (zh)	2014-11-17	2021-12-28	阿尔尼拉姆医药品有限公司	载脂蛋白C3（APOC3）iRNA组合物及其使用方法
CN107106493A (zh)	2014-11-21	2017-08-29	西北大学	球形核酸纳米颗粒缀合物的序列特异性细胞摄取
CN107532162A (zh)	2014-12-12	2018-01-02	托德·M·伍尔夫	用于利用寡核苷酸编辑细胞中核酸的组合物和方法
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en)	2015-01-06	2020-10-06	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
US10538763B2 (en)	2015-01-16	2020-01-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of DUX4
US10968449B2 (en)	2015-01-22	2021-04-06	Monsanto Technology Llc	Compositions and methods for controlling Leptinotarsa
WO2016118812A1 (en)	2015-01-23	2016-07-28	Vanderbilt University	A robust interferometer and methods of using same
JP6929791B2 (ja)	2015-02-09	2021-09-01	デュークユニバーシティ	エピゲノム編集のための組成物および方法
WO2016130806A2 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
US10450342B2 (en)	2015-02-23	2019-10-22	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
US20180200387A1 (en)	2015-02-23	2018-07-19	Crispr Therapeutics Ag	Materials and methods for treatment of human genetic diseases including hemoglobinopathies
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
WO2016142948A1 (en)	2015-03-11	2016-09-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Decoy oligonucleotides for the treatment of diseases
WO2016157175A1 (en)	2015-03-27	2016-10-06	Yeda Research And Development Co. Ltd.	Methods of treating motor neuron diseases
BR112017020750A2 (pt)	2015-03-27	2018-06-26	Harvard College	células t modificadas e métodos de produção e utilização das mesmas
WO2016164463A1 (en)	2015-04-07	2016-10-13	The General Hospital Corporation	Methods for reactivating genes on the inactive x chromosome
US10745702B2 (en)	2015-04-08	2020-08-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
BR112017023754B1 (pt)	2015-05-04	2022-08-09	Beeologics, Inc.	Composições inseticidas, e uso de um ácido nucleico
EP3294280A1 (de)	2015-05-11	2018-03-21	Yeda Research and Development Co., Ltd.	Citrinhemmer zur behandlung von krebs
UY36703A (es)	2015-06-02	2016-12-30	Monsanto Technology Llc	Composiciones y métodos para la administración de un polinucleótido en una planta
EP3302030A4 (de)	2015-06-03	2019-04-24	Monsanto Technology LLC	Verfahren und zusammensetzungen zum einführen von nukleinsäuren in pflanzen
EP3307316A1 (de)	2015-06-12	2018-04-18	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
CA2990852A1 (en)	2015-06-26	2016-12-29	Beth Israel Deaconess Medical Center, Inc.	Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
CA2991045A1 (en)	2015-06-29	2017-01-05	Caris Science, Inc.	Therapeutic oligonucleotides binding c1q
CA2991598A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
WO2017019918A1 (en)	2015-07-28	2017-02-02	Caris Science, Inc.	Targeted oligonucleotides
WO2017021963A1 (en)	2015-08-03	2017-02-09	Biokine Therapeutics Ltd.	Cxcr4 binding agents for treatment of diseases
WO2017021961A1 (en)	2015-08-04	2017-02-09	Yeda Research And Development Co. Ltd.	Methods of screening for riboswitches and attenuators
CN108271387B (zh)	2015-08-07	2023-06-27	箭头药业股份有限公司	乙型肝炎病毒感染的RNAi疗法
SG10202007937SA (en)	2015-09-02	2020-09-29	Alnylam Pharmaceuticals Inc	PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP3353297A1 (de)	2015-09-24	2018-08-01	Crispr Therapeutics AG	Neuartige familie von rna-programmierbaren endonukleasen und deren verwendung in der genomeditierung und anderen anwendungen
EP3353303B1 (de)	2015-09-25	2023-08-02	Ionis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur modulation von ataxin 3-expression
US11021707B2 (en)	2015-10-19	2021-06-01	Phio Pharmaceuticals Corp.	Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
US20180311176A1 (en)	2015-10-26	2018-11-01	Translate Bio Ma, Inc.	Nanoparticle formulations for delivery of nucleic acid complexes
AU2016344609B2 (en)	2015-10-28	2022-05-12	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of duchenne muscular dystrophy
IL295097A (en)	2015-10-30	2022-09-01	Genentech Inc	Anti-htra1 antibodies and methods of using them
AU2016349954B2 (en)	2015-11-05	2022-08-25	Antisense Therapeutics Ltd	Mobilizing leukemia cells
MX2018005332A (es)	2015-11-06	2018-11-09	Crispr Therapeutics Ag	Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a.
WO2017081686A1 (en)	2015-11-10	2017-05-18	B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University	Means and methods for reducing tumorigenicity of cancer stem cells
US11001622B2 (en)	2015-11-19	2021-05-11	The Brigham And Women's Hospital, Inc.	Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
WO2017093804A2 (en)	2015-12-01	2017-06-08	Crispr Therapeutics Ag	Materials and methods for treatment of alpha-1 antitrypsin deficiency
EP3389670A4 (de)	2015-12-04	2020-01-08	Ionis Pharmaceuticals, Inc.	Verfahren zur behandlung von brustkrebs
US10993995B2 (en)	2015-12-07	2021-05-04	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for pompe disease
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
BR112018012894A2 (pt)	2015-12-23	2018-12-04	Crispr Therapeutics Ag	materiais e métodos para tratamento de esclerose lateral amiotrófica e/ou degeneração lobular frontotemporal
CA3006599A1 (en)	2016-01-05	2017-07-13	Ionis Pharmaceuticals, Inc.	Methods for reducing lrrk2 expression
US10627396B2 (en)	2016-01-29	2020-04-21	Vanderbilt University	Free-solution response function interferometry
US20190038771A1 (en)	2016-02-02	2019-02-07	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
JP2019509721A (ja)	2016-02-04	2019-04-11	キュリス，インコーポレイテッド	突然変異体スムースンド及びその使用方法
EP3416689B1 (de)	2016-02-18	2023-01-18	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn syndrome
WO2017147087A1 (en)	2016-02-25	2017-08-31	The Brigham And Women's Hospital, Inc.	Treatment methods for fibrosis targeting smoc2
EP3429632B1 (de)	2016-03-16	2023-01-04	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von erblicher haemochromatose
CA3013799A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Methods of modulating keap1
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
CN109715802A (zh)	2016-03-18	2019-05-03	卡里斯科学公司	寡核苷酸探针及其用途
SG10202010261YA (en)	2016-04-18	2020-11-27	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
WO2017205686A1 (en)	2016-05-25	2017-11-30	Caris Science, Inc.	Oligonucleotide probes and uses thereof
JP2019518028A (ja)	2016-06-10	2019-06-27	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
US11236339B2 (en)	2016-06-17	2022-02-01	Ionis Pharmaceuticals, Inc.	Modulation of GYS1 expression
WO2017223528A1 (en)	2016-06-24	2017-12-28	The Scripps Research Institute	Novel nucleoside triphosphate transporter and uses thereof
WO2018002762A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
US11564997B2 (en)	2016-06-29	2023-01-31	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
US11427838B2 (en)	2016-06-29	2022-08-30	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
CA3029141A1 (en)	2016-07-06	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of pain related disorders
US11801313B2 (en)	2016-07-06	2023-10-31	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
US11253601B2 (en)	2016-07-11	2022-02-22	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
US20190247436A1 (en)	2016-07-21	2019-08-15	Maxcyte, Inc.	Methods and compositions for modifying genomic dna
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
JOP20170161A1 (ar)	2016-08-04	2019-01-30	Arrowhead Pharmaceuticals Inc	عوامل RNAi للعدوى بفيروس التهاب الكبد ب
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
HUE059718T2 (hu)	2016-09-02	2022-12-28	Dicerna Pharmaceuticals Inc	4'-foszfát analógok és azokat tartalmazó oligonukleotidok
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
EP3522898A4 (de)	2016-10-06	2020-05-27	Ionis Pharmaceuticals, Inc.	Verfahren zum konjugieren von oligomeren verbindungen
CA3037046A1 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
US11033570B2 (en)	2016-12-02	2021-06-15	Cold Spring Harbor Laboratory	Modulation of Lnc05 expression
WO2018111834A1 (en)	2016-12-13	2018-06-21	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
EP3555292A1 (de)	2016-12-16	2019-10-23	Alnylam Pharmaceuticals, Inc.	Verfahren zur behandlung oder prävention von ttr-assoziierten krankheiten unter verwendung von transthyretin (ttr)-irna-zusammensetzungen
IL301053A (en)	2017-01-23	2023-05-01	Regeneron Pharma	HSD17B13 variants and their uses
WO2018154418A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
US20200216857A1 (en)	2017-02-22	2020-07-09	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585899A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
CA3054031A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Compositions and methods for gene editing
WO2018154439A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
WO2018165564A1 (en)	2017-03-09	2018-09-13	Ionis Pharmaceuticals, Inc.	Morpholino modified oligomeric compounds
WO2018183969A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
TWI801377B (zh)	2017-04-18	2023-05-11	美商阿尼拉製藥公司	治療具有ｂ型肝炎病毒（ｈｂｖ）感染之個體之方法
AU2018256435A1 (en)	2017-04-20	2019-11-07	Atyr Pharma, Inc.	Compositions and methods for treating lung inflammation
WO2018193428A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
US11872239B2 (en)	2017-04-20	2024-01-16	Synthena Ag	Modified oligomeric compounds comprising tricyclo-DNA nucleosides and uses thereof
WO2018195486A1 (en)	2017-04-21	2018-10-25	The Broad Institute, Inc.	Targeted delivery to beta cells
EP3621981A2 (de)	2017-05-12	2020-03-18	CRISPR Therapeutics AG	Materialien und verfahren zur manipulation von zellen und deren verwendungen in der immunonkologie
SG11202000167SA (en)	2017-07-11	2020-02-27	Synthorx Inc	Incorporation of unnatural nucleotides and methods thereof
AU2018301477A1 (en)	2017-07-13	2020-02-27	Alnylam Pharmaceuticals Inc.	Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
CA3069909A1 (en)	2017-07-13	2019-02-14	Northwestern University	General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
CA3071016A1 (en)	2017-08-03	2019-02-07	Synthorx, Inc.	Cytokine conjugates for the treatment of autoimmune diseases
WO2019036613A1 (en)	2017-08-18	2019-02-21	Ionis Pharmaceuticals, Inc.	MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
WO2019051173A1 (en)	2017-09-08	2019-03-14	Ionis Pharmaceuticals, Inc.	MODULATORS OF SMAD7 EXPRESSION
KR20200089656A (ko)	2017-09-19	2020-07-27	알닐람 파마슈티칼스 인코포레이티드	트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
CA3079172A1 (en)	2017-10-17	2019-04-25	Crispr Therapeutics Ag	Compositions and methods for gene editing for hemophilia a
EP3701029A1 (de)	2017-10-26	2020-09-02	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
US11866701B2 (en)	2017-11-01	2024-01-09	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
MA50578A (fr)	2017-11-09	2021-09-15	Vertex Pharma	Systèmes crispr/cas pour le traitement de dmd
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
EP3710587A1 (de)	2017-11-16	2020-09-23	Alnylam Pharmaceuticals, Inc.	Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon
EP3714054A1 (de)	2017-11-20	2020-09-30	Alnylam Pharmaceuticals, Inc.	Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
US10662425B2 (en)	2017-11-21	2020-05-26	Crispr Therapeutics Ag	Materials and methods for treatment of autosomal dominant retinitis pigmentosa
US20200384033A1 (en)	2017-12-05	2020-12-10	Vertex Pharmaceuticals Incorporated	Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
CN111801417A (zh)	2017-12-14	2020-10-20	克里斯珀医疗股份公司	新的rna-可编程的内切核酸酶系统及其在基因组编辑和其他应用中的用途
KR20200110655A (ko)	2017-12-18	2020-09-24	알닐람 파마슈티칼스 인코포레이티드	고이동성 그룹 박스-1 (hmgb1) irna 조성물 및 이의 사용 방법
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
EP3728595A1 (de)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
CA3084632A1 (en)	2017-12-21	2019-06-27	Crispr Therapeutics Ag	Materials and methods for treatment of usher syndrome type 2a
CA3088180A1 (en)	2018-01-12	2019-07-18	Crispr Therapeutics Ag	Compositions and methods for gene editing by targeting transferrin
MA51645A (fr)	2018-01-15	2020-11-25	Ionis Pharmaceuticals Inc	Modulateurs de l'expression de dnm2
US20190233816A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
US11566236B2 (en)	2018-02-05	2023-01-31	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
MA51788A (fr)	2018-02-05	2020-12-16	Vertex Pharma	Substances et méthodes pour traiter des hémoglobinopathies
WO2019155465A1 (en)	2018-02-08	2019-08-15	Yeda Research And Development Co. Ltd.	Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
US20210130824A1 (en)	2018-02-16	2021-05-06	Crispr Therapeutics Ag	Compositions and methods for gene editing by targeting fibrinogen-alpha
AR114445A1 (es)	2018-02-26	2020-09-09	Synthorx Inc	Conjugados de il-15, y sus usos
WO2019169219A1 (en)	2018-03-02	2019-09-06	Ionis Pharmaceuticals, Inc.	Modulators of irf4 expression
US11732260B2 (en)	2018-03-02	2023-08-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-β precursor protein
EP3762395A1 (de)	2018-03-07	2021-01-13	Sanofi	Nukleotidvorläufer, nukleotidanaloga und oligomere verbindungen damit
WO2019183150A1 (en)	2018-03-19	2019-09-26	Casebia Therapeutics Limited Liability Partnership	Novel rna-programmable endonuclease systems and uses thereof
WO2019183440A1 (en)	2018-03-22	2019-09-26	Ionis Pharmaceuticals, Inc.	Methods for modulating fmr1 expression
CA3095545A1 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
EP3772928A4 (de)	2018-04-06	2021-12-29	Children's Medical Center Corporation	Zusammensetzungen und verfahren zur prägung der umprogrammierung und modulation von somatischen zellen
US11365416B2 (en)	2018-04-11	2022-06-21	Ionis Pharmaceuticals, Inc.	Modulators of EZH2 expression
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
BR112020020957B1 (pt)	2018-05-09	2022-05-10	Ionis Pharmaceuticals, Inc	Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
PE20212131A1 (es)	2018-05-09	2021-11-05	Ionis Pharmaceuticals Inc	Compuestos y metodos para reducir de la expresion de atxn3
TW202016304A (zh)	2018-05-14	2020-05-01	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
JP2021526823A (ja)	2018-06-14	2021-10-11	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｓｔｍｎ２発現を増加させるための化合物及び方法
AU2019294838A1 (en)	2018-06-27	2021-01-07	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing LRRK2 expression
BR112020025824A2 (pt)	2018-06-28	2021-03-23	Crispr Therapeutics Ag	composições e métodos para edição genômica por inserção de polinucleotídeos doadores
US11078486B2 (en)	2018-07-25	2021-08-03	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing ATXN2 expression
AR114551A1 (es)	2018-08-13	2020-09-16	Alnylam Pharmaceuticals Inc	COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO
US20210348162A1 (en)	2018-08-16	2021-11-11	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
US20210292766A1 (en)	2018-08-29	2021-09-23	University Of Massachusetts	Inhibition of Protein Kinases to Treat Friedreich Ataxia
EP3849584A4 (de)	2018-09-14	2022-06-22	Northwestern University	Programmierung von proteinpolymerisation mit dna
AU2019344776A1 (en)	2018-09-18	2021-01-21	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (KHK) iRNA compositions and methods of use thereof
WO2020081843A1 (en)	2018-10-17	2020-04-23	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for delivering transgenes
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
MX2021005758A (es)	2018-11-15	2021-09-21	Ionis Pharmaceuticals Inc	Moduladores de la expresión de irf5.
IL263184A (en)	2018-11-21	2020-05-31	Yarden Yosef	Method of treating cancer and compositions for same
US20210332495A1 (en)	2018-12-06	2021-10-28	Northwestern University	Protein Crystal Engineering Through DNA Hybridization Interactions
EA202191736A1 (ru)	2018-12-20	2021-10-01	Вир Байотекнолоджи, Инк.	Комбинированная терапия hbv
CA3123617A1 (en)	2018-12-20	2020-06-25	Praxis Precision Medicines, Inc.	Compositions and methods for the treatment of kcnt1 related disorders
CN113557023A (zh)	2019-01-16	2021-10-26	建新公司	Serpinc1 iRNA组合物及其使用方法
US11214803B2 (en)	2019-01-31	2022-01-04	Ionis Pharmaceuticals, Inc.	Modulators of YAP1 expression
MA54952A (fr)	2019-02-06	2022-05-11	Synthorx Inc	Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
MA54951A (fr)	2019-02-15	2021-12-22	Bayer Healthcare Llc	Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
WO2020171889A1 (en)	2019-02-19	2020-08-27	University Of Rochester	Blocking lipid accumulation or inflammation in thyroid eye disease
WO2020170240A1 (en)	2019-02-21	2020-08-27	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Method for reduction drug-induced nephrotoxicity
WO2020176771A1 (en)	2019-02-27	2020-09-03	Ionis Pharmaceuticals, Inc.	Modulators of malat1 expression
SG11202109741VA (en)	2019-03-12	2021-10-28	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
CN113728104B (zh)	2019-03-29	2023-10-27	Ionis制药公司	用于调节ube3a-ats的化合物和方法
BR112021018739A2 (pt)	2019-03-29	2022-05-03	Dicerna Pharmaceuticals Inc	Composições e métodos para o tratamento de doenças ou distúrbios associados a kras
BR112021021686A2 (pt)	2019-05-03	2022-03-22	Dicerna Pharmaceuticals Inc	Moléculas inibidoras de ácido nucleico de fita dupla com fitas senso curtas
EP3966327A1 (de)	2019-05-08	2022-03-16	Vertex Pharmaceuticals Incorporated	Crispr/cas all-in-two-vektorsystemen zur behandlung von dmd
CN114126628A (zh)	2019-05-13	2022-03-01	维尔生物科技有限公司	用于治疗乙型肝炎病毒(hbv)感染的组合物及方法
EP3983543A4 (de)	2019-06-14	2023-05-03	The Scripps Research Institute	Reagenzien und verfahren zur replikation, transkription und translation in halbsynthetischen organismen
WO2020254872A2 (en)	2019-06-17	2020-12-24	Crispr Therapeutics Ag	Methods and compositions for improved homology directed repair
WO2021021673A1 (en)	2019-07-26	2021-02-04	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating gfap
WO2021022109A1 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4013870A1 (de)	2019-08-13	2022-06-22	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
MX2022001776A (es)	2019-08-15	2022-03-17	Synthorx Inc	Terapias de combinacion de inmuno oncologia con conjugados de il-2.
WO2021030778A1 (en)	2019-08-15	2021-02-18	Ionis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds and uses thereof
AU2020337869A1 (en)	2019-08-23	2022-03-03	Synthorx, Inc.	IL-15 conjugates and uses thereof
US20220290152A1 (en)	2019-09-03	2022-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
CA3150082A1 (en)	2019-09-10	2021-03-18	Jerod PTACIN	IL-2 CONJUGATES AND METHODS OF USE FOR TREATING AUTOIMMUNE DISEASES
WO2021067747A1 (en)	2019-10-04	2021-04-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
WO2021076828A1 (en)	2019-10-18	2021-04-22	Alnylam Pharmaceuticals, Inc.	Solute carrier family member irna compositions and methods of use thereof
WO2021081026A1 (en)	2019-10-22	2021-04-29	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof
US20230040920A1 (en)	2019-11-01	2023-02-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
JP2023500661A (ja)	2019-11-01	2023-01-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法
JP2022554272A (ja)	2019-11-04	2022-12-28	シンソークス，インコーポレイテッド	インターロイキン１０コンジュゲートおよびその使用
MX2022005692A (es)	2019-11-13	2022-06-08	Alnylam Pharmaceuticals Inc	Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt).
US20230056569A1 (en)	2019-11-22	2023-02-23	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
CA3159501A1 (en)	2019-11-27	2021-06-03	Brian Joseph CAFFERTY	Methods of synthesizing rna molecules
WO2021108291A1 (en) *	2019-11-27	2021-06-03	Alnylam Pharmaceuticals, Inc.	Synthesis of 3'-rna oligonucleotides
IL293824A (en)	2019-12-13	2022-08-01	Alnylam Pharmaceuticals Inc	Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them
TW202138559A (zh)	2019-12-16	2021-10-16	美商阿尼拉製藥公司	含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
WO2021122944A1 (en)	2019-12-18	2021-06-24	Alia Therapeutics Srl	Compositions and methods for treating retinitis pigmentosa
AU2021207504A1 (en)	2020-01-15	2022-08-04	Dicerna Pharmaceuticals, Inc.	4'-O-methylene phosphonate nucleic acids and analogues thereof
US20230057461A1 (en)	2020-01-27	2023-02-23	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
IL295445A (en)	2020-02-10	2022-10-01	Alnylam Pharmaceuticals Inc	Preparations and methods for silencing vegf-a expression
WO2021167841A1 (en)	2020-02-18	2021-08-26	Alnylam Pharmaceuticals, Inc.	Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
KR20220148230A (ko)	2020-02-28	2022-11-04	아이오니스 파마수티컬즈, 인코포레이티드	Smn2를 조절하기 위한 화합물 및 방법
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
CA3174725A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
JP2023519274A (ja)	2020-03-26	2023-05-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	コロナウイルスｉＲＮＡ組成物およびその使用方法
US20230190785A1 (en)	2020-03-30	2023-06-22	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
CA3179411A1 (en)	2020-04-06	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing myoc expression
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
MX2022012561A (es)	2020-04-07	2022-11-07	Alnylam Pharmaceuticals Inc	Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).
MX2022013525A (es)	2020-04-27	2023-01-24	Alnylam Pharmaceuticals Inc	Composiciones de agentes de ácido ribonucleico de interferencia (arni) de apolipoproteína e (apoe) y métodos de uso de las mismas.
BR112022021136A2 (pt)	2020-04-30	2022-11-29	Alnylam Pharmaceuticals Inc	Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
JP2023524065A (ja)	2020-05-01	2023-06-08	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ａｔｘｎ１を調節するための化合物及び方法
EP4150089A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231698A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
CA3162416C (en)	2020-05-15	2023-07-04	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
EP4150087A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
EP4150076A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231685A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
EP4153746A1 (de)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
US20230203484A1 (en)	2020-05-22	2023-06-29	Wave Life Sciences Ltd.	Double stranded oligonucleotide compositions and methods relating thereto
US11408000B2 (en)	2020-06-03	2022-08-09	Triplet Therapeutics, Inc.	Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
EP4161552A1 (de)	2020-06-05	2023-04-12	The Broad Institute, Inc.	Zusammensetzungen und verfahren zur behandlung von neoplasien
EP4162050A1 (de)	2020-06-09	2023-04-12	Alnylam Pharmaceuticals, Inc.	Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
IL299063A (en)	2020-06-18	2023-02-01	Alnylam Pharmaceuticals Inc	Xanthine dehydrogenase (xdh) RNA compositions and methods of using them
WO2021262840A1 (en)	2020-06-24	2021-12-30	Vir Biotechnology, Inc.	Engineered hepatitis b virus neutralizing antibodies and uses thereof
EP4171648A1 (de)	2020-06-25	2023-05-03	Synthorx, Inc.	Immunonkologische kombinationstherapie mit il-2-konjugaten und anti-egfr-antikörpern
MX2022016338A (es)	2020-06-29	2023-01-24	Ionis Pharmaceuticals Inc	Compuestos y metodos para modular la plp1.
EP4192505A1 (de)	2020-08-04	2023-06-14	Dicerna Pharmaceuticals, Inc.	Systemische verabreichung von oligonukleotiden
WO2022066847A1 (en)	2020-09-24	2022-03-31	Alnylam Pharmaceuticals, Inc.	Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
WO2022070107A1 (en)	2020-09-30	2022-04-07	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis
EP3978608A1 (de)	2020-10-05	2022-04-06	SQY Therapeutics	Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
EP4225917A1 (de)	2020-10-05	2023-08-16	Alnylam Pharmaceuticals, Inc.	G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230084203A (ko)	2020-10-09	2023-06-12	신톡스, 인크.	Il-2 접합체 및 펨브롤리주맙을 사용한 면역 종양 병용 요법
WO2022076859A1 (en)	2020-10-09	2022-04-14	Synthorx, Inc.	Immuno oncology therapies with il-2 conjugates
WO2022079719A1 (en)	2020-10-15	2022-04-21	Yeda Research And Development Co. Ltd.	Method of treating myeloid malignancies
CA3198823A1 (en)	2020-10-21	2022-04-28	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
EP4232582A1 (de)	2020-10-23	2023-08-30	Alnylam Pharmaceuticals, Inc.	Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022103999A1 (en)	2020-11-13	2022-05-19	Alnylam Pharmaceuticals, Inc.	COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2023549563A (ja)	2020-11-18	2023-11-27	アイオーニスファーマシューティカルズ，インコーポレーテッド	アンジオテンシノーゲン発現を調節するための化合物及び方法
EP4247949A1 (de)	2020-11-23	2023-09-27	Alpha Anomeric SAS	Nukleinsäureduplexe
EP4256053A1 (de)	2020-12-01	2023-10-11	Alnylam Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
JP2024501288A (ja)	2020-12-23	2024-01-11	フラッグシップパイオニアリングイノベーションズシックス，エルエルシー	修飾ｔｒｅｍの組成物及びその使用
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022174101A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Skin cancer combination therapy with il-2 conjugates and cemiplimab
TW202302148A (zh)	2021-02-12	2023-01-16	美商欣爍克斯公司	使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
KR20230146048A (ko)	2021-02-12	2023-10-18	알닐람 파마슈티칼스 인코포레이티드	슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법
EP4298220A1 (de)	2021-02-25	2024-01-03	Alnylam Pharmaceuticals, Inc.	Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
BR112023016645A2 (pt)	2021-02-26	2023-11-14	Alnylam Pharmaceuticals Inc	Composições de irna de ceto-hexoquinase (khk) e métodos de uso das mesmas
BR112023017737A2 (pt)	2021-03-04	2023-10-03	Alnylam Pharmaceuticals Inc	Composições de irna de angiopoietina-semelhantes 3 (angptl3) e métodos de uso das mesmas
WO2022192038A1 (en)	2021-03-12	2022-09-15	Northwestern University	Antiviral vaccines using spherical nucleic acids
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
IL307239A (en)	2021-03-29	2023-11-01	Alnylam Pharmaceuticals Inc	Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
EP4314293A1 (de)	2021-04-01	2024-02-07	Alnylam Pharmaceuticals, Inc.	Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
IL307926A (en)	2021-04-26	2023-12-01	Alnylam Pharmaceuticals Inc	Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
EP4330396A1 (de)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022235537A1 (en)	2021-05-03	2022-11-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
WO2022245583A1 (en)	2021-05-18	2022-11-24	Alnylam Pharmaceuticals, Inc.	Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
EP4341405A1 (de)	2021-05-20	2024-03-27	Korro Bio, Inc.	Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
WO2022256395A1 (en)	2021-06-02	2022-12-08	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
TW202313117A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
KR20240017911A (ko)	2021-06-04	2024-02-08	알닐람 파마슈티칼스 인코포레이티드	인간 염색체 9 개방 해독 프레임 72(C9orf72) iRNA 제제 조성물 및 이의 사용 방법
AR126070A1 (es)	2021-06-08	2023-09-06	Alnylam Pharmaceuticals Inc	Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
KR20240021218A (ko)	2021-06-11	2024-02-16	바이엘 악티엔게젤샤프트	신규 유형 v rna 프로그래밍가능 엔도뉴클레아제 시스템
BR112023026050A2 (pt)	2021-06-18	2024-03-05	Ionis Pharmaceuticals Inc	Compostos e métodos para reduzir expressão de ifnar1
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
WO2023278410A1 (en)	2021-06-29	2023-01-05	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
KR20240026203A (ko)	2021-06-30	2024-02-27	알닐람 파마슈티칼스 인코포레이티드	안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
TW202333748A (zh)	2021-07-19	2023-09-01	美商艾拉倫製藥股份有限公司	用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
WO2023003995A1 (en)	2021-07-23	2023-01-26	Alnylam Pharmaceuticals, Inc.	Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2023009687A1 (en)	2021-07-29	2023-02-02	Alnylam Pharmaceuticals, Inc.	3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
AU2022323090A1 (en)	2021-08-03	2024-02-01	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof
TW202337474A (zh)	2021-08-04	2023-10-01	美商艾拉倫製藥股份有限公司	用於緘默血管收縮素原（ＡＧＴ）的ｉＲＮＡ組成物及方法
CA3228733A1 (en)	2021-08-13	2023-02-16	Alnylam Pharmaceuticals, Inc.	Factor xii (f12) irna compositions and methods of use thereof
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
WO2023044370A2 (en)	2021-09-17	2023-03-23	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing complement component 3 (c3)
CA3232420A1 (en)	2021-09-20	2023-03-23	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
CA3234835A1 (en)	2021-10-22	2023-04-27	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
AU2022378567A1 (en)	2021-10-29	2024-04-11	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
WO2023076450A2 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2023118349A1 (en)	2021-12-21	2023-06-29	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2023118068A1 (en)	2021-12-23	2023-06-29	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023177866A1 (en)	2022-03-18	2023-09-21	Dicerna Pharmaceuticals, Inc.	Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy- nucleotide
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
WO2023237587A1 (en)	2022-06-10	2023-12-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2024026474A1 (en)	2022-07-29	2024-02-01	Regeneron Pharmaceuticals, Inc.	Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
WO2024059165A1 (en)	2022-09-15	2024-03-21	Alnylam Pharmaceuticals, Inc.	17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2024056880A2 (en)	2022-09-16	2024-03-21	Alia Therapeutics Srl	Enqp type ii cas proteins and applications thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2002773B (en) *	1977-08-10	1982-03-03	Brown R	Nucleotide inhibitor of protein synthesis
US4210746A (en) *	1978-08-10	1980-07-01	National Research Development Corporation	Nucleotide inhibitor of protein synthesis
US4464359A (en) *	1981-04-10	1984-08-07	Research Corporation	(2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof
US4515781A (en) *	1983-02-23	1985-05-07	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	2',5'-Riboadenylate-morpholinoadenylate nucleotides
US4565696A (en) *	1983-08-03	1986-01-21	The Regents Of The University Of California	Production of immunogens by antigen conjugation to liposomes
FR2567892B1 (fr) *	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US4663161A (en) *	1985-04-22	1987-05-05	Mannino Raphael J	Liposome methods and compositions
US4781871A (en) *	1986-09-18	1988-11-01	Liposome Technology, Inc.	High-concentration liposome processing method
US4924624A (en) *	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5866787A (en) *	1993-03-08	1999-02-02	Cleveland Clinic Foundation	Transgenic plants co-expressing a functional human 2-5A system

1987
- 1987-10-22 US US07/112,591 patent/US4924624A/en not_active Expired - Lifetime
1988
- 1988-10-18 DE DE3856326T patent/DE3856326T2/de not_active Expired - Fee Related
- 1988-10-18 EP EP95202077A patent/EP0694559B1/de not_active Expired - Lifetime
- 1988-10-18 AT AT88909900T patent/ATE135579T1/de not_active IP Right Cessation
- 1988-10-18 AT AT95202077T patent/ATE178902T1/de not_active IP Right Cessation
- 1988-10-18 WO PCT/US1988/003634 patent/WO1989003683A1/en active IP Right Grant
- 1988-10-18 DE DE3855135T patent/DE3855135T2/de not_active Expired - Fee Related
- 1988-10-18 EP EP88909900A patent/EP0389521B1/de not_active Expired - Lifetime
- 1988-10-18 CA CA000580426A patent/CA1339953C/en not_active Expired - Fee Related
- 1988-10-18 JP JP63509144A patent/JP2733777B2/ja not_active Expired - Fee Related
- 1988-10-18 AU AU26280/88A patent/AU2628088A/en not_active Abandoned
1992
- 1992-07-16 US US07/915,771 patent/US5405939A/en not_active Expired - Lifetime
1994
- 1994-12-02 US US08/348,419 patent/US5556840A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA1339953C (en)	1998-07-14
ATE178902T1 (de)	1999-04-15
EP0694559A2 (de)	1996-01-31
WO1989003683A1 (en)	1989-05-05
US5556840A (en)	1996-09-17
EP0389521A1 (de)	1990-10-03
AU2628088A (en)	1989-05-23
ATE135579T1 (de)	1996-04-15
JP2733777B2 (ja)	1998-03-30
JPH04500795A (ja)	1992-02-13
US5405939A (en)	1995-04-11
US4924624A (en)	1990-05-15
DE3855135D1 (de)	1996-04-25
EP0694559A3 (de)	1996-07-31
EP0389521B1 (de)	1996-03-20
DE3856326T2 (de)	1999-12-02
EP0389521A4 (en)	1992-02-05
DE3856326D1 (de)	1999-05-20
EP0694559B1 (de)	1999-04-14

Legal Events

Date	Code	Title	Description
1997-04-17	8364	No opposition during term of opposition
2006-08-17	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
DE3855135T2 (de)	1996-09-05	2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen
DE69330274T2 (de)	2001-11-15	Enantiomerisch reine beta-d-dioxolan-nukleoside
DE69025529D1 (de)	1996-04-04	Weitere antivirale Pyrimidin-Nukleosiden
DK108491A (da)	1991-06-07	Nucleosider og nucleosidanaloge samt farmaceutiske praeparater indeholdende disse forbindelser
DE68920125D1 (de)	1995-02-02	Pyrimidindion-Derivate, Verfahren zu deren Herstellung und diese enthaltende antiarrythmische Mittel.
HK1002108A1 (en)	1998-07-31	Optically active pyridonecarboxylic acid derivatives
DK232989D0 (da)	1989-05-12	Antiviralt praeparat
ATE33653T1 (de)	1988-05-15	Antivirale purinderivate.
DK291390A (da)	1990-12-07	Terapeutiske anvendelser af 2',5'-oligoadenylatderivater
ATE90685T1 (de)	1993-07-15	Disaccharidderivate.
GR3019893T3 (en)	1996-08-31	Novel S-adenosyl methionine decarboxylase inhibitors
NO176609C (no)	1995-05-03	Fremgangsmåte til fremstilling av et sterkt vannlöselig, stabilt, krystallinsk salt av 2',3'-dideoksyinosin, 2',3'-dideoksy-2',3'didehydrotymidin eller 2',3'dideoksy-2'-fluorinosin
FR2608157B1 (fr)	1989-09-08	Nouveaux derives de l'azaspirodecane, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant et intermediaires
FR2577553B1 (fr)	1991-06-21	Derives de l'ergoline et leurs sels formes par addition avec des acides, et leurs applications therapeutiques
ES2045146T3 (es)	1994-01-16	Avermectinas etiladas.
DE68914809T2 (de)	1994-08-11	Antivirale Wirkstoffe.
FI812773L (fi)	1982-03-13	Foerfarande foer framstaellning av n-/4-/(2,4-diamino-6-pteridinyl)-metyl/metylamino/benzoyl/glutaminsyra
ATE101119T1 (de)	1994-02-15	Butensaeure-amide, deren salze, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung.